GPCR agonist-induced transactivation of the EGFR upregulates MLC II expression and promotes hypertension in insulin-resistant rats

Cardiovascular Research

Volumn 87, Issue 1, 2010, Pages 177-186

  Nagareddy, Prabhakara Reddy ^a   MacLeod, Kathleen M ^a   McNeill, John H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Epidermal growth factor receptor; Hypertension; Insulin resistance; Matrix metalloproteinase; Vascular smooth muscle

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALPHA 1 ADRENERGIC RECEPTOR; CHOLESTEROL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FRUCTOSE; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GLUCOSE; INSULIN; MATRILYSIN; MYOSIN LIGHT CHAIN KINASE; SERUM RESPONSE FACTOR; SMALL INTERFERING RNA; TRIACYLGLYCEROL; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIAC MYOSIN; EGFR PROTEIN, RAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MMP2 PROTEIN, RAT; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 2; PHENYLEPHRINE; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SYSTOLIC HYPERTENSION; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; TIME; UPREGULATION; VASOCONSTRICTION; WISTAR RAT;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADRENERGIC ALPHA-AGONISTS; ANIMALS; CARDIAC MYOSINS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FRUCTOSE; HYPERTENSION; INSULIN RESISTANCE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE INHIBITORS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOSIN LIGHT CHAINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENYLEPHRINE; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, ALPHA-1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UP-REGULATION; VASOCONSTRICTION;

EID: 77955160619     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq030     Document Type: Article

References (54)

1. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-1904.
2. Fernandez-Patron C. Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxi-dative stress, and hypertrophic growth downstream of vasoactive G-protein-coupled receptors? Can J Physiol Pharmacol 2007;85:97-104.
3. Touyz RM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003;5:155-164.
4. Harris RC. EGF receptor activation by G-protein coupled receptors. Kidney Int 2000; 58:898-899.
5. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 1998;273:8890-8896.
6. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004;94:68-76.
7. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci 2001;947:42-54; discussion 54-145
8. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999;402:884-888.
9. Shah BH, Catt KJ. A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy. Trends Pharmacol Sci 2003;24:239-244.
10. Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab 2004;15: 241-243.
11. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906-911.
12. DeLano FA, Schmid-Schonbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension 2008; 52:415-423.
13. Hao L, Nishimura T, Wo H, Fernandez-Patron C. Vascular responses to alpha1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Arterioscler Thromb Vasc Biol 2006;26:819-825.
14. Morimoto Y, Nishikawa K, Ohashi M. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Life Sci 1997;61:795-803.
15. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S et al. Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009;119:2480-2489.
16. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311-320.
17. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999;104:447-457.
18. Nagareddy PR, Chow FL, Hao L, Wang X, Nishimura T, MacLeod KM et al. Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochondrial ATP synthesis. Cardiovasc Res 2009;84:368-377.
19. Battell ML, Delgatty HL, McNeill JH. Sodium selenate corrects glucose tolerance and heart function in STZ diabetic rats. Mol Cell Biochem 1998;179:27-34.
20. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R et al. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol 2006;26:1473-1480.
21. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002;277:1531-1537.
22. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000;87:670-676.
23. Crabbe T, O'Connell JP, Smith BJ, Docherty AJ. Reciprocated matrix metalloprotei-nase activation: a process performed by interstitial collagenase and progelatinase A. Biochemistry 1994;33:14419-14425.
24. Barille S, Bataille R, Rapp MJ, Harousseau JL, Amiot M. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 1999;163:5723-5728.
25. Treisman R. The serum response element. Trends Biochem Sci 1992;17:423-426.
26. Han YJ, Hu WY, Piano M, de Lanerolle P. Regulation of myosin light chain kinase expression by angiotensin II in hypertension. Am J Hypertens 2008;21:860-865.
27. Han YJ, Hu WY, Chernaya O, Antic N, Gu L, Gupta M et al. Increased myosin light chain kinase expression in hypertension: Regulation by serum response factor via an insertion mutation in the promoter. Mol Biol Cell 2006;17:4039-4050.
28. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res 2001;89:488-495.
29. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol 2003;35:577-593.
30. Rivera VM, Miranti CK, Misra RP, Ginty DD, Chen RH, Blenis J et al. A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Mol Cell Biol 1993;13:6260-6273.
31. Chung AW, Booth AD, Rose C, Thompson CR, Levin A, van Breemen C. Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction. J Vasc Res 2008;45: 357-362.
32. Yasmin SM, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
33. Murphy G, Willenbrock F, Crabbe T, O'Shea M, Ward R, Atkinson S et al. Regulation of matrix metalloproteinase activity. Ann N Y Acad Sci 1994;732:31-41.
34. Bode W, Maskos K. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 2003;384: 863-872.
35. Hao F, Yu JD. High glucose enhance expression of matrix metalloproteinase-2 in smooth muscle cells. Acta Pharmacol Sin 2003;24:534-538.
36. Sachidanandam K, Portik-Dobos V, Harris AK, Hutchinson JR, Muller E, Johnson MH et al. Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes. Diabetes 2007;56:2753-2758.
37. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH et al. Diabetes melli-tus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001;88:1291-1298.
38. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005;56:173-189.
39. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997;15:519-526.
40. Sato H, Kita M, Seiki M. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 1993;268:23460-23468.
41. Nagareddy PR, Soliman H, Lin G, Rajput PS, Kumar U, McNeill JH et al. Selective inhibition of protein kinase C beta(2) attenuates inducible nitric oxide synthase-mediated cardiovascular abnormalities in streptozotocin-induced diabetic rats. Diabetes 2009; 58:2355-2364.
42. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 2004;53:2910-2920.
43. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88: 787-835. ix.
44. Takada J, Machado MA, Peres SB, Brito LC, Borges-Silva CN, Costa CE et al. Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance associated with loss of adipose mass. Metabolism 2007;56:977-984.
45. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL. Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res 1999;84:505-515.
46. de Vries-Smits AM, Burgering BM, Leevers SJ, Marshall CJ, Bos JL. Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature 1992;357: 602-604.
47. Turjanski AG, Vaque JP, Gutkind JS. MAP kinases and the control of nuclear events. Oncogene 2007;26:3240-3253.
48. Shaw PE, Saxton J. Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. Int J Biochem Cell Biol 2003;35:1210-1226.
49. Zhang HM, Li L, Papadopoulou N, Hodgson G, Evans E, Galbraith M et al. Mitogen-induced recruitment of ERK and MSK to SRE promoter complexes by ternary complex factor Elk-1. Nucleic Acids Res 2008;36:2594-2607.
50. Tran LT, MacLeod KM, McNeill JH. Endothelin-1 modulates angiotensin II in the development of hypertension in fructose-fed rats. Mol Cell Biochem 2009;325:89-97.
51. Verma S, Skarsgard P, Bhanot S, Yao L, Laher I, McNeill JH. Reactivity of mesenteric arteries from fructose hypertensive rats to endothelin-1. Am J Hypertens 1997;10:1010-1019.
52. Jiang J, Tran L, Vasudevan H, Xia Z, Yuen VG, McNeill JH. Endothelin-1 blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat. Can J Physiol Pharmacol 2007;85:422-429.
53. Shimamoto K, Ura N. Mechanisms of insulin resistance in hypertensive rats. Clin Exp Hypertens 2006;28:543-552.
54. Arellano-Plancarte A, Hernandez-Aranda J, Catt KJ, Olivares-Reyes JA. Angiotensin-induced EGF receptor transactivation inhibits insulin signaling in C9 hepatic cells. Biochem Pharmacol 2010;79:733-745